AliveCor today announced a Series F financing led by GE Healthcare.
The FDA-approved personal electrocardiogram technology company did not disclose the size of the funding round. NGK-NTK, through a CVC partnership with Pegasus Tech Ventures, also joined the round. The round also included existing investors Khosla Ventures, Bold Capital Partners, Qualcomm Ventures and WP Global Partners.
GE’s cash injection comes five months after GE Healthcare and AliveCor announced a partnership. Individuals with an AliveCor KardiaMobile 6L ECG machine outside of the hospital can send their data directly to GE Healthcare’s Muse Cardiac Management System. Physicians can then view and evaluate the information. This is hopefully to spot atrial fibrillation and other heart conditions before sending someone to the hospital.
“GE Healthcare is committed to delivering advanced technologies that better connect data and create actionable insights for clinicians to serve patients inside and outside of the hospital,” said Tom. Westrick, president and CEO of GE Healthcare’s Patient Care Solutions business.
Westrick, who will join AliveCor’s Board of Directors, added, “This strategic partnership with AliveCor strengthens our ability to deliver connected care that empowers clinicians to make faster, more informed decisions and helps improve outcomes. for patients.
AliveCor CEO Priya Abani said the funding round will accelerate growth in new strategic sectors and markets. To date, Mountain View, Calif.-based AliveCor has served over 2 million customers. He has recorded over 160 million ECGs worldwide.
Portable ECG monitors are a hot space in medical technology. A host of companies are looking to provide a better alternative to the traditional Holter monitors that doctors have attached to their patients when they suspect atrial fibrillation. Other companies competing in the space include Baxter’s iRhythm and Bardy Diagnostics.